Loading
A phase 2 trial of Durvalumab, Carboplatin, Cisplatin in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of AZD2811 + Durvalumab in ES-SCLC is a phase 2 interventional study registered as NCT04745689 by AstraZeneca, with 31 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2022-06-18. Interventions recorded: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide. Conditions listed: Small-Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
31 enrolled.
95% CI 4.14 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-03-27), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS) in Maintenance Participants | AZD2811 + Durvalumab | 9 | 9.99 months | - | - | link |
Shares Extensive-stage small-cell lung cancer, Etoposide, Cisplatin, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Durvalumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Cisplatin, Carboplatin.